Efzofitimod was found to be generally safe and well tolerated by patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) in a proof-of-concept Phase 2 study. No treatment-related serious side effects were reported, with efzofitimod showing early signs of efficacy. In addition, the last patient visit has been completed in…
Read more
The immune signaling protein interleukin-40, or IL-40, may be involved in developing systemic sclerosis (SSc), a study from the Czech Republic suggests. Elevated levels of IL-40 were found in the bloodstream of adults with SSc and correlated with worse disease activity, digestive problems, and markers of inflammation and fibrosis.
The first patient with systemic sclerosis (SSc) has been dosed in a Phase 1 trial of Adicet Bio’s investigational CAR T-cell therapy for autoimmune conditions, called ADI-001, the company has announced. Recruitment in the open-label trial (NCT06375993) is ongoing at one site in California. It’s expected…
Becoming educated and informed about scleroderma is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your scleroderma journey.
There is no cure for scleroderma yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
